Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

The need for dialysis after TAVR increases mortality

Courtesy of Dr. Carlos Fava.

Stage III or higher renal impairment is frequent before TAVR, and the need for new dialysis after the procedure may reach up to 20%. Within that percentage, 5% may require permanent dialysis, which increases mortality up to 9 times at one year. In that sense, factors leading to that complication have not been well studied yet.

La diálisis nueva post TAVI aumenta la mortalidad.

This study included prospectively 6464 patients from 2007 to 2014. Among them, 117 were subjected to dialysis before the procedure (1.8%) and 202 required dialysis after percutaneous valve implantation (3.1%). The follow-up was 625 days (268-1208).

 

There were no significant differences between populations, except for the fact that non-transfemoral access and Edwards valves were more frequent among patients requiring new dialysis.


Read also: Post TAVR Dialysis: a Severe Complication Less and Less Frequent”.


The need for new dialysis ranged from 6.1% in 2007-2008 to 2.3% in 2013-2014. The need for new dialysis after TAVR was independently associated with renal impairment a year after the procedure, impaired left ventricular function, diabetes, use of an Edwards valve, a non-transfemoral approach, need for open surgery, and moderate-to-severe aortic regurgitation.

 

Furthermore, upon follow-up, this need was associated with increased 30-day mortality (hazard ratio [HR]: 6.44; 95% confidence interval [CI]: 4.87 to 8.53) and 4-year mortality (HR: 3.54; 95% CI: 2.99 to 4.19; p < 0.001), compared with patients who did not require dialysis.

 

Conclusion

The proportion of patients needing dialysis after TAVR has decreased over time. Post-TAVR dialysis was associated with increased mortality.

 

Editorial Comment

While it is widely known that the need for dialysis increases the rates of other complications and mortality for all endovascular and surgical procedures, this analysis shows that this complication decreases significantly as we move along the learning curve.


Read also: A Simple Electrocardiography to Predict Mortality in TAVR”.


On the other hand, we must remain alert to comorbidities and use the lowest possible contrast to reduce the incidence of this unpleasant complication.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Dialysis Following Transcatheter Aortic Valve Implantation, Risk Factors and Outcomes. An Analisis From the UK TAVI Registry.

Reference: Charles Ferro, et al. J Am Coll Cardiol Intevn Article in Press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVI in TAVI: Clinical and Hemodynamic Outcomes According to the Type of Prosthesis Used in TAVI-in-TAVI

With the expansion of TAVI to younger and lower surgical risk patients, bioprosthetic valve degeneration and the need for repeat interventions are expected to...

Percutaneous Closure of Patent Foramen Ovale in Patients Over 60 Years Old With Cryptogenic Stroke: A Safe and Effective Strategy?

Cryptogenic stroke accounts for up to one-third of all ischemic strokes and remains strongly associated with the presence of a patent foramen ovale (PFO),...

Left Atrial Appendage Closure: Implantation Depth Could Determine Thrombosis Risk

Left atrial appendage closure (LAAC) has undergone significant advances over the past two decades. This progress has been driven by the development of new...

Influence of cusp-overlap and three-cusp coplanar techniques on new-onset conduction disturbances after TAVI

New-onset conduction disturbances remain one of the most frequent complications after transcatheter aortic valve implantation (TAVI), being associated with worse long-term clinical outcomes. Among...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | Could clopidogrel replace aspirin as monotherapy after PCI?

This presentation, delivered during EuroPCR 2026, analyzed the clinical outcomes of clopidogrel monotherapy versus aspirin in patients who remained event-free for 12 months after...

EuroPCR 2026 | Are bioresorbable stents making a comeback? Five-year results of FUTURE-II with Firesorb

The first bioresorbable coronary scaffolds generated great expectations because of their potential to restore vascular physiology after device resorption. However, early studies such as...

EuroPCR 2026 | Coronary bioadaptor: fewer events regardless of IVUS or FFR guidance

Despite the increasing use of intracoronary imaging and physiology, stent-related events continue to occur at an annual rate of approximately 2–3% beyond the first...